Vancomycin therapeutics and monitoring: A contemporary approach

Internal Medicine Journal

Volumn 43, Issue 2, 2013, Pages 110-119

  Avent, M L ^a,b   Vaska, V L ^a   Rogers, B A ^a   Cheng, A C ^c   van Hal, S J ^e   Holmes, N E ^d   Howden, B P ^d   Paterson, D L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d AUSTIN HEALTH   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Clinical pharmacology; Computerized models; Drug monitoring; Pharmacokinetics

Indexed keywords

BETA LACTAM ANTIBIOTIC; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BAYES THEOREM; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER PROGRAM; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; HEALTH CARE PERSONNEL; HUMAN; INFORMATION TECHNOLOGY; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OBESITY; PEDIATRICS; PHARMACODYNAMICS; POPULATION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; STAPHYLOCOCCUS INFECTION; TREATMENT INDICATION;

ANIMALS; BAYES THEOREM; DRUG MONITORING; HUMANS; LINEAR MODELS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84873729935     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12036     Document Type: Review

References (57)

1. Gyssens IC. Vancomycin. In: Grayson ML, ed. Kucers' the Use of Antibiotics, Vol. 1, 6th edn. London: Hodder Arnold; 2010; 569-600.
2. Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM etal. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82: 333-339.
3. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
4. Mohammedi I, Descloux E, Argaud L, Le Scanff J, Robert D. Loading dose of vancomycin in critically ill patients: 15mg/kg is a better choice than 500mg. Int J Antimicrob Agents 2006; 27: 259-262.
5. Wai AO, Lo AM, Abdo A, Marra F. Vancomycin-induced acute interstitial nephritis. Ann Pharmacother 1998; 32: 1160-1164.
6. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107-1115.
7. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-2144.
8. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995; 15: 85-91.
9. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-687.
10. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985; 16: 235-241.
11. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990; 10: 378-382.
12. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M etal. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-327.
13. Davis RL, Smith AL, Koup JR. The 'red man's syndrome' and slow infusion of vancomycin. Ann Intern Med 1986; 104: 285-286.
14. Wazny LD, Daghigh B. Desensitization protocols for vancomycin hypersensitivity. Ann Pharmacother 2001; 35: 1458-1464.
15. Geraci JE, Heilman FR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. Proc Staff Meet Mayo Clin 1958; 33: 172-181.
16. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1988; 3: 376-386.
17. Morris A, Ward C. High incidence of vancomycin-associated leucopenia and neutropenia in a cardiothoracic surgical unit. J Infect 1991; 22: 217-223.
18. Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related? Ann Pharmacother 2011; 45: 629-638.
19. EUCAST [homepage on the Internet]. Vaxjo SVSa. Vancomycin/Staphylococcus aureus EUCAST MIC Distribution Reference Database [cited 2012 May 30]. Available from URL: http://miceucastorg/Eucast2/regShowjsp?Id=1214
20. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A7. Wayne, PA: CLSI; 2006.
21. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50: 3039-3047.
22. Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y etal. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55: 3870-3881.
23. Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC. Vancomycin-intermediate Staphylococcus aureus: the contribution of selected gene mutations in clinical isolates. Antimicrob Agents Chemother 2012; 56: 5845-5851.
24. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ etal. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
25. van Hal SJ, Jones M, Gosbell IB, Paterson DL. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One 2011; 6: e21217.
26. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 405-410.
27. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-771.
28. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clin Infect Dis 2011; 52: 997-1002.
29. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-451.
30. Lodise TP, Miller CD, Graves J, Evans A, Graffunder E, Helmecke M etal. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008; 62: 1138-1141.
31. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-624.
32. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P etal. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-528.
33. Moise PA, Smyth DS, Robinson DA, El-Fawal N, McCalla C, Sakoulas G. Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies. J Antimicrob Chemother 2009; 63: 873-876.
34. Miller CE, Batra R, Cooper BS, Patel AK, Klein J, Otter JA etal. An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection. Clin Infect Dis 2012; 54: 591-600.
35. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV etal. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204: 340-347.
36. Holmes NE, Johnson PDR, Howden BP. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol 2012; 50: 2548-2552.
37. van Hal SJ, Paterson DL. New Gram-positive antibiotics: better than vancomycin? Curr Opin Infect Dis 2011; 24: 515-520.
38. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME etal. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665.
39. Lomaestro BM. Vancomycin dosing and monitoring 2 years after the guidelines. Expert Rev Anti Infect Ther 2011; 9: 657-667.
40. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A etal. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54: 621-629.
41. Therapeutic Guidelines. Antibiotic, 14th edn. Melbourne, VIC: Therapeutic Guidelines; 2010.
42. Health Communication Network. Australian Medicines Handbook. Adelaide, SA: Australian Medicines Handbook; 2012; v.
43. Gonzales M, Pepin J, Frost EH, Carrier JC, Sirard S, Fortier LC etal. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 2010; 10: 363.
44. Vandecasteele SJ, De Vriese AS. Vancomycin dosing in patients on intermittent hemodialysis. Semin Dial 2011; 24: 50-55.
45. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-580.
46. Dehority W. Use of vancomycin in pediatrics. Pediatr Infect Dis J 2010; 29: 462-464.
47. Kaplan EL. Vancomycin in infants and children: a review of pharmacology and indications for therapy and prophylaxis. J Antimicrob Chemother 1984; 14(Suppl D): 59-66.
48. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann Pharmacother 2011; 45: 757-763.
49. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MVN etal. Vancomycin pharmacodynamics in Staphylococcus aureus bacteremia. ICAAC 2011; 51: A-1681.
50. Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 2012; 32: 195-201.
51. Kullar R, Leonard SN, Davis SL, Delgado G Jr, Pogue JM, Wahby KA etal. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 2011; 31: 441-448.
52. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21: 362-369.
53. Bayard DS, Jelliffe RW. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn 2004; 31: 75-107.
54. Macdonald I, Staatz CE, Jelliffe RW, Thomson AH. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit 2008; 30: 67-74.
55. Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied Pharmacokinetics and Pharmacodynamics, 4th edn. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006.
56. Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011; 41: 441-449.
57. Aubron C, Corallo CE, Nunn MO, Dooley MJ, Cheng AC. Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients. Ann Pharmacother 2011; 45: 1193-1198.